![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Johnson & Johnson to Settle Remicade Antitrust Lawsuit for $25 Million
Johnson & Johnson to Settle Remicade Antitrust Lawsuit for $25 Million
Johnson & Johnson (J&J) has reportedly agreed to pay $25 million to settle a lawsuit over an alleged antitrust scheme involving its blockbuster immunosuppressive drug Remicade (infliximab).
The settlement, filed in a federal court in the Eastern District of Pennsylvania, is intended to resolve class-action claims against the company for its alleged obstruction of insurers covering generic versions of Remicade, which is a tumor necrosis-factor blocking drug.
Remicade, which gained initial FDA approval in 1998, is currently approved for multiple indications, including Crohn’s disease and ulcerative colitis. The drug earned more than $3 billion worldwide for J&J in 2021.
Upcoming Events
-
18Jul
-
21Oct